IOT Innovotech Inc

Innovotech Inc. (TSX VENTURE:IOT) today announced its unaudited financial and
operational results for the three month period ended March 31, 2009.


Highlights:

- 87% conversion of warrants further strengthens cash reserves to support
product development


- Reduced revenue due to delays and postponement of research contracts 

- Company business model proves its value during the current economic and
financial crisis


"The improvement in cash reserves strengthens a product development effort that
should result in product sales revenue in 2009 " said James Timourian, Chief
Financial Officer of Innovotech. "While contract research revenue continues to
be affected by the reduction in activity of small biotechnology companies, a
broadened sales effort has led to an improved order book with larger clients in
the second quarter. The company's focus on cash flow through contract research
and developing innovative products with short regulatory pathways, such as the
bioFILM PA(TM) kit and Agress(TM) seed treatment, is proving its value during
the current financial crisis."





Financial Summary

                       Three month period ended    Three month period ended
                                 March 31, 2009              March 31, 2008

Revenues                                216,000                     428,286

G&A                                     246,036                     241,777

R&D                                     192,150                     103,406

Net Income (Loss)                      (367,269)                    (96,725)

Share Price                              $  .84                      $  .90

Cash Reserves                         2,210,484                   2,139,507



About Innovotech Inc:

Innovotech is a product development company focusing on the development of
solutions to medical, agricultural and industrial problems caused by microbial
biofilms. Biofilms are protected communities of microorganisms which are very
common and very difficult to treat due to their inherent resistance. The company
currently has two products in advanced stages of development: bioFILM PA is a
diagnostic kit which assists physicians in the selection of the most effective
antibiotic treatment of patients with chronic lung infections. Agress(TM) is a
novel seed treatment product which protects seeds during the critical
germination and emergence stage from bacterial and fungal infection. Both
products were developed against the corresponding organisms present as biofilms
as opposed to the free-floating, planktonic form. 


This document may contain forward-looking statements that are predictive in
nature and subject to risks and uncertainties that cannot be predicted or
quantified; consequently, actual results may differ materially from past results
and those expressed or implied by any forward-looking statements. Factors that
could cause or contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of predicting
regulatory outcomes; changes in the value of the Canadian dollar; the Company's
reliance on a small number of customers including government organizations;
fluctuations in operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships; uncertainty
related to intellectual property protection and potential costs associated with
its defense; the Company's exposure to lawsuits and other matters beyond the
control of management. Should known or unknown risks or uncertainties
materialize, or should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company undertakes no
obligation to publicly make or update any forward-looking statements, except as
required by applicable law.

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jul 2023 to Jul 2024